Prescient Therapeutics Limited (ASX:PTX) has announced that Mr. Steven Yatomi-Clarke, the Managing Director and Chief Executive Officer, will be stepping down in early 2025 to pursue a new appointment. Mr. Yatomi-Clarke intends to remain in his position until the end of February 2025, while the company conducts a search for a new CEO.
Prescient Chair, Steve Engle, expressed deep appreciation for Steven's outstanding leadership and strategic vision in building the company and an international R&D team over the last eight years. He highlighted Mr. Yatomi-Clarke's significant contributions to the development of PTX-100 oncology candidate and the establishment of Prescient as a recognized leader in novel cancer therapies. Mr. Yatomi-Clarke also shared his pride in the company's achievements during his tenure and expressed excitement about its prospects and upcoming milestones.
Prescient Therapeutics (ASX:PTX) has announced the upcoming transition of its CEO, Mr. Steven Yatomi-Clarke, in early 2025. The company will conduct a search for a new CEO to continue its momentum. Mr. Yatomi-Clarke, while stepping down, will remain available as a consultant to provide ongoing assistance. Additionally, he has been selected as the inaugural CEO of Aurora Biosynthetics, a private company spearheading the development of an RNA ecosystem in Australia. The announcement reflects Prescient's commitment to seamless leadership transition and continued pursuit of its corporate goals and initiatives.